Logo of CSL (ASX:CSL)Latest CSL (ASX:CSL) News

Page 1
Page 1 of 3

Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Prominence Energy doubled as hydrogen speculation drove the week’s biggest move, while takeover news lifted RAS Technology and Cleanaway.
Zip Co and several resource developers fell as investors weighed costs, capital needs and delivery risks.
Logan Eniac
24 Oct 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

CSL faces class action over alleged FY26 disclosure failures

CSL has been named as the defendant in a group proceeding filed in the Supreme Court of Victoria, covering investors who acquired certain securities between February 2025 and May 2026. The company denies liability and says it will vigorously defend allegations involving continuous disclosure and FY26 performance statements.
Ada Torres
22 Oct 2026

CSL appoints ViiV chief Deborah Waterhouse as CEO from February 2027

CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
21 Oct 2026

Market Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Exploration stocks dominated the biggest weekly moves, while several companies warned that cash, debt or approvals could decide what happens next.
Alvo Minerals led the market after heavy rare earth results, but company announcements remained a mixed source of confidence and concern.
Logan Eniac
10 Oct 2026

CSL Commits US$355 Million to Rare Kidney and Liver Drug Partnership

CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.
Victor Sage
5 Oct 2026

Market Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Gold, rare earths and energy shares led a busy week, while major company results brought large gains and steep sell-offs. Corporate deals, new project studies and rising dividends drew buyers, but some stocks fell despite stronger earnings.
Logan Eniac
22 Aug 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

CSL Reports US$15.8 Billion Revenue but Statutory Loss of US$2.6 Billion Amid Major Restructuring

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.
Ada Torres
18 Aug 2026

Market Wrap - Week 20 (11 May -> 15 May) 2026

Capital raisings, resource updates and Medicare news drove the week’s biggest share moves. The sharpest gains came from silver and tungsten juniors, while the heaviest fall came from a deeply discounted equity raising.
Logan Eniac
16 May 2026

CSL Cuts FY26 Revenue Forecast, Flags $5 Billion Asset Impairments

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.
Ada Torres
11 May 2026

Market Wrap - Week 7 (9 Feb -> 13 Feb) 2026

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.
Logan Eniac
14 Feb 2026